BC
XENE icon

Broadfin Capital’s Xenon Pharmaceuticals XENE Stock Holding History

Broadfin Capital’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-895,553
Closed -$11.8M – 58
2018
Q3 		$11.8M Buy
+895,553
New +$10.4M 1.74% 24

Other funds holding XENE

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Broadfin Capital's XENE Position: Q4 2018 in Review

Broadfin Capital sold out of Xenon Pharmaceuticals (XENE) in Q4 2018, closing a stake of 895,553 shares — an estimated $11.8M sold.

Broadfin Capital first reported a position in XENE in Q3 2018 and held it in 1 quarter. The position peaked at $11.8M in Q3 2018. 58 funds tracked by Wall St. Rank hold XENE as of Q4 2018.

  • Broadfin Capital reported no remaining Xenon Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Broadfin Capital sold 895,553 Xenon Pharmaceuticals shares in Q4 2018, an estimated $11.8M.
  • Broadfin Capital first reported a position in Xenon Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • Broadfin Capital's Xenon Pharmaceuticals position peaked at $11.8M in Q3 2018.
  • 58 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q4 2018.

Based on Broadfin Capital's 13F filing for Q4 2018, filed 14 Feb 2019.